5FLUOROURACIL EFFECTS ON URACIL-RICH MRNA STABILITY
5FLUOROURACIL EFFECTS ON URACIL-RICH MRNA STABILITY
批准号:
2012360
负责人:
THOMAS D. SCHMITTGEN
金额:
$10.32万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-06-01 至 2000-05-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: Although 5-fluorouracil (FU) has been used in the treatment of
cancer for nearly four decades, the drug's mechanism of anti-tumor activity
is not completely understood. FU is readily incorporated into al species of
RNA, however, a precise mechanism that describes the ensuing toxicity
remains to be established. A number of the most labile mRNas known contain
an adenylate, uridylate-rich element (ARE) that selectively targets the mRNA
for rapid degradation. Since most ARE-containing mRNas encode for proteins
that are involved in critical processes such as cell growth, differentiation
and development, interference with stability regulation may be deleterious
to the cell. This application will investigate if incorporation of FU into
ARE-containing mRNAs enhance their stability. The effect that FU has on the
stability of mRNAs containing three different AREs will be studied. The
c-myc, GM-CSF or c-jun AREs were fused in frame to portions of a gene
encoding the long-lived beta globin mRNA. The chimeric genes were placed
downstream from the serum-inducible, c-fos promotor and were transfected
into NIH 3T3 fibroblasts. Quiescent cells will be induced with serum plus
FU. The newly transcribed mRNAs will incorporate the FU and the MRNA
half-life will be calculated from the transcript decay. A multiplex
polymerase chain reaction (PCR) assay will be used to evaluate the stability
of a select number of ARE-containing and ARE-lacking mRNAs from tumor cell
lines treated with FU. Differential display PCR will determine what mRNAs
are differentially stabilized as FU becomes incorporated into mRNA. Cloning
and sequencing the differentially stabilized mRNAs will determine what
proportion of the differentially stabilized mRNAs contain the ARE. The
affinity of uracil- and FU-substituted AREs to trans-acting protein factors
that bind to the ARE and regulate mRNA stability will be examined by a gel
mobility shift assay. Cells exposed to FU will be assayed for the amount of
free versus bound protein factors to determine if the affinity following
exposure to FU. A complete understanding of the unique anti-tumor activity
of FU may enhance its clinical effectiveness and aid in the design of new
anti-cancer drugs.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Diverse gene expression pattern during 5-fluorouridine-induced apoptosis.
5-氟尿苷诱导的细胞凋亡过程中不同的基因表达模式。
DOI:
--
发表时间:
2005
期刊:
International journal of oncology.
影响因子:
--
作者:
[Schmittgen,ThomasD, Gissel,KariA, Zakrajsek,BrianA, Lawrence,BPaige, Liu,Qian, Jupe,EldonR, Lerner,MeganR, Do,SonV, Brackett,DanielJ]
通讯作者:
Brackett,DanielJ
R21 MPI microRNA directed therapy for treating early stage pancreatic cancer
-
批准号:10577609
-
项目类别:
-
资助金额:$17.82万
-
财政年份:2023
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Pilot Project 3: Contribution of Racial Disparity towards the Early Development of Pancreatic Cancer
-
批准号:10006214
-
项目类别:
-
资助金额:$11.3万
-
财政年份:2018
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Project 3 ADM
-
批准号:10762126
-
项目类别:
-
资助金额:$11.6万
-
财政年份:2018
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
miRNA Biomarkers for Hepatocellular Carcinoma Associated with Viral Hepatitis
-
批准号:8520269
-
项目类别:
-
资助金额:$16.77万
-
财政年份:2012
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
miRNA Biomarkers for Hepatocellular Carcinoma Associated with Viral Hepatitis
-
批准号:8364566
-
项目类别:
-
资助金额:$25.1万
-
财政年份:2012
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Real-time PCR expression profiling of microRNA
-
批准号:7137111
-
项目类别:
-
资助金额:$21.02万
-
财政年份:2006
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Real-time PCR expression profiling of microRNA
-
批准号:7596042
-
项目类别:
-
资助金额:$20.92万
-
财政年份:2006
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Real-time PCR expression profiling of microRNA
-
批准号:7632039
-
项目类别:
-
资助金额:$20.92万
-
财政年份:2006
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Real-time PCR expression profiling of microRNA
-
批准号:7808845
-
项目类别:
-
资助金额:$20.91万
-
财政年份:2006
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Micro RNA Expression and Cancer
-
批准号:6764682
-
项目类别:
-
资助金额:$13.46万
-
财政年份:2004
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Micro RNA Expression and Cancer
-
批准号:6895843
-
项目类别:
-
资助金额:$13.46万
-
财政年份:2004
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
APTAMERS AS CELLULAR TARGETING AGENTS
-
批准号:2839727
-
项目类别:
-
资助金额:$14.1万
-
财政年份:1999
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
APTAMERS AS CELLULAR TARGETING AGENTS
-
批准号:6174299
-
项目类别:
-
资助金额:$14.15万
-
财政年份:1999
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
ANTICANCER DRUG EFFECTS ON RNA PROCESSING
-
批准号:2105844
-
项目类别:
-
资助金额:$2.99万
-
财政年份:1995
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
ANTICANCER DRUG EFFECTS ON RNA PROCESSING
-
批准号:2105843
-
项目类别:
-
资助金额:$2.86万
-
财政年份:1994
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Pilot Project
-
批准号:9788341
-
项目类别:
-
资助金额:$2.23万
-
财政年份:--
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Pilot Project 3: Contribution of Racial Disparity towards the Early Development of Pancreatic Cancer
-
批准号:10006223
-
项目类别:
-
资助金额:$2.18万
-
财政年份:--
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
Pilot Project 3: Contribution of Racial Disparity towards the Early Development of Pancreatic Cancer
-
批准号:9634749
-
项目类别:
-
资助金额:$9.68万
-
财政年份:--
-
负责人:THOMAS D. SCHMITTGEN
-
依托单位:
海外基金